Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Pharmacologic blockade of 5LO decreases Aβ peptides levels and deposition in the 3×Tg mice via the γ-secretase pathway. by Jin Chu (358006)

Decreased LIN-35/Rb contributes to the RNAi hypersensitivity of <i>mir-35-41(gk262)</i> worms. by Katlin B. Massirer (178591)

“…After normalization to tubulin the average and standard deviation from 4 independent experiments was calculated with wild type levels set to one (Student's t-test *p<4×10⁻⁵). (C) PAGE Northern blot analysis of RNA from wild type and <i>lin-35(n475)</i> embryos shows similar levels of pre- and mature miR-35 expression. …”

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Baseline patient characteristics across neutralizing monoclonal antibody trials. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses by baseline anti-spike neutralizing response assay positivity. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for nMAbs, among patients alive and with day 90 antibody and antigen measures (Sensitivity Analysis). by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Longitudinal antibody and antigen responses to treatment vs placebo day 1–90 for neutralizing monoclonal antibodies, among patients alive and with day 90 antibody and antigen measu... by Elizabeth S. Munroe (21568166)

Subjects:

Study Flow Diagram. by Elizabeth S. Munroe (21568166)

Subjects:

Resveratrol decreases activated-STAT1 levels in the nucleus of cytokine-stimulated HT-29 cells more efficiently than 5-ASA. by Diana Serra (455187)

Decreased erythropoiesis related gene expression in the bone marrow of <i>Thra1</i>^PV/+ mice. by Sunmi Park (2051092)

Increased accumulation of mutant huntingtin aggregates and decreased mobility of autophagosomes in the axon of AP-4 ε KO hippocampal neurons. by Raffaella De Pace (5147120)

Decreased macrophage content per lesion area in atherosclerotic lesions from ABCA1 KO→LDLr KO mice. by Bart Lammers (302835)